Last edition
News about "Alesta acquisition"
BioMarin to Acquire Alesta Therapeutics for Oral Hypophosphatasia Therapy ALE1
BioMarin will acquire Alesta Therapeutics for USD 275 million upfront, gaining ALE1, a potential first oral therapy for hypophosphatasia, plus milestone payments.
Alesta Acquisition | 20/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members